In the cutting-edge medical field, a Japanese venture company – TOKIWA-Bio, sets goal to contribute to the world!
“Practical application of clinical iPS cell production technology” adopted for Program for Creating STart-ups from Advanced Research and Technology (START)
TOKIWA-Bio Inc. was established.
Recognized by AIST as AIST start-ups and established headquarters and research facility in AIST Tsukuba Central Office
Head office moved to Tsukuba Center Inc.(TCI)
TOKIWA-Bio Inc. raised 330 million yen through third-party allotment.
TOKIWA-Bio Inc. was adopted by Japan Agency for Medical Research and Development(AMED) Project for “Genetic and Cellular Therapeutic Research and Development”
TOKIWA-Bio Inc. was adopted by Japan Agency for Medical Research and Development(AMED) Project for “Basic Technology Development for Industrialization of Regenerative Medicine and Gene Therapy(regenerative medicine seeds development acceleration support)”